Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/30/2012EP2457582A1 Method and compositions for controlling ectoparasites
05/30/2012EP2457574A1 Amide derivatives of hyaluronic acid in osteoarthrosis
05/30/2012EP2457573A1 Methods of use of glycomimetics with replacements for hexoses and N-Acetyl hexosamines
05/30/2012EP2457572A1 Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases
05/30/2012EP2457571A1 Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
05/30/2012EP2457570A1 Fentanyl-containing adhesive preparation for external use
05/30/2012EP2457569A1 Use of active pharmaceutical compounds for the treatment of central nervous system conditions
05/30/2012EP2457568A1 Composition comprising an avermectine and metronidazole in particular for treating rosacea
05/30/2012EP2457567A1 Agent having neurotrophic factor-like activity
05/30/2012EP2457566A1 EXTERNAL PREPARATION CONTAINING NSAIDs AND METHOD FOR PRODUCING THE EXTERNAL PREPARATION
05/30/2012EP2457565A1 Transdermal therapeutic system containing rotigotin
05/30/2012EP2457563A1 Zero-order modified release solid dosage forms
05/30/2012EP2457562A1 Zero-order modified release solid dosage forms
05/30/2012EP2457561A1 Tablet having hollow structure
05/30/2012EP2457560A1 Topical compositions
05/30/2012EP2456870A1 Antisense oligomers targeting pcsk9
05/30/2012EP2456869A1 Inhibitors of mtor kinase as anti-viral agents
05/30/2012EP2456868A1 Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
05/30/2012EP2456790A1 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
05/30/2012EP2456775A1 Method of making cefquinome particles
05/30/2012EP2456774A1 Fused aminodihydro-oxazine derivatives
05/30/2012EP2456772A2 Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
05/30/2012EP2456771A1 Fused aminodihydropyrimidone derivatives
05/30/2012EP2456770A2 Benzoquinolizinium salt derivatives as anticancer agents
05/30/2012EP2456767A1 Pyridone glucokinase activators
05/30/2012EP2456765A1 Imidazole derivatives as mglur5 antagonists
05/30/2012EP2456763A1 Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders
05/30/2012EP2456762A1 Dual-acting oxazole antihypertensive agents
05/30/2012EP2456761A2 Potent small molecule inhibitors of autophagy and methods of use thereof
05/30/2012EP2456757A2 Hdac inhibitors and therapeutic methods using the same
05/30/2012EP2456754A1 Acyl guanidine derivatives modulating the hedgehog protein signaling pathway
05/30/2012EP2456750A2 New form of the aminoindan mesylate derivative rasaginline mesylate
05/30/2012EP2456471A2 Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
05/30/2012EP2456465A2 Material system comprising endoperoxide adapting to decomposition, and applications
05/30/2012EP2456464A1 Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
05/30/2012EP2456449A2 Composition and method to alleviate joint pain
05/30/2012EP2456448A1 Methods of attenuating the loss of functional status
05/30/2012EP2456445A1 Agent for the treatment of skin conditions
05/30/2012EP2456444A1 Certain chemical entities, compositions and methods
05/30/2012EP2456443A1 Treatment of liver disorders with pi3k inhibitors
05/30/2012EP2456442A1 1h-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis
05/30/2012EP2456441A1 Combination therapies with ck2 modulators
05/30/2012EP2456440A1 Quinolinone pde2 inhibitors
05/30/2012EP2456439A2 A stable pharmaceutical omeprazole formulation for oral administration
05/30/2012EP2456438A2 Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
05/30/2012EP2456437A1 Combinations of curcummoids and mtor inhibitors for the treatment of tauopathies
05/30/2012EP2456436A1 3-phenoxymethylpyrrolidine compounds
05/30/2012EP2456435A1 Heteroaryl benzamides, compositions and methods of use
05/30/2012EP2456434A1 Galantamine amino acid and peptide prodrugs and uses thereof
05/30/2012EP2456433A2 Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine
05/30/2012EP2456432A1 Methods and compositions to reduce oxidative stress
05/30/2012EP2456431A1 Cell protection in dialysis patients by administration of a creatine compound
05/30/2012EP2456430A1 Beta 2 adrenergic receptor agonists such as terbutaline for use in the treatment of nocturnal hypoglycemia
05/30/2012EP2456429A1 Composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
05/30/2012EP2456428A1 Selective cb2 receptor agonists for use in the prevention or treatment of alcoholic liver disease
05/30/2012EP2456427A1 Hot-melt extruded controlled release dosage form
05/30/2012EP2456426A1 Ferric citrate dosage forms
05/30/2012EP2456425A1 Tamper-resistant dosage form for oxidation-sensitive opioids
05/30/2012EP2456424A1 Oxidation-stabilized tamper-resistant dosage form
05/30/2012EP2456423A2 Treatment of hyperproliferative conditions
05/30/2012EP2456422A2 Topical pharmaceutical composition including rel-n-[6-[(2r,6s)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-41-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide.
05/30/2012EP2456421A1 Multi-layered gradient vaginal ring
05/30/2012EP2456419A1 A3 adenosine receptor ligands for modulation of pigmentation
05/30/2012EP2456318A1 Crude caffeine complex, improved food products using the crude caffeine complex, and methods of use thereof
05/30/2012EP2456310A1 Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators
05/30/2012EP2456309A1 Therapeutic compounds
05/30/2012EP2456307A1 Isoform selective phospholipase d inhibitors
05/30/2012EP2456306A1 Vitamin c and vitamin k, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant
05/30/2012EP2456304A1 Methods of modulation of branched chain acids and uses thereof
05/30/2012EP2456300A2 Insecticidal and/or repulsive process
05/30/2012EP2231652B1 Novel 2-hetaryl thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
05/30/2012EP2214673B1 Phenyl-substituted piperazino-dihydrothienopyrimidines
05/30/2012EP2146984B1 Hepatitis c virus inhibitors
05/30/2012EP2137166B1 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
05/30/2012EP2137146B1 Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester
05/30/2012EP2118088B1 Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
05/30/2012EP2081946B1 Adenosine derivatives for the treatment of pain
05/30/2012EP2055703B1 Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and pharmaceutical comprising the compound
05/30/2012EP2049478B1 Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
05/30/2012EP2021002B1 Pharmaceutical composition comprising olmesartan medoxomil
05/30/2012EP2013185B1 Novel compounds
05/30/2012EP1940842B1 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
05/30/2012EP1893039B1 Method for treatment and prevention of respiratory insufficiency
05/30/2012EP1891002B1 Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia
05/30/2012EP1851209B1 [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadph quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular
05/30/2012EP1797858B1 Composition for oral cavity
05/30/2012EP1797093B1 Novel 3-methyl-7-butinyl-xanthines, production thereof, and use thereof as medicaments
05/30/2012EP1771453B1 Hepatitis c inhibitor dipeptide analogs
05/30/2012EP1757604B1 Process for producing solifenacin or its salt
05/30/2012EP1744764B1 Liposomal formulations of anthracycline agents and cytidine analogs
05/30/2012EP1702919B1 Novel 2-heteroaryl-substituted benzimidazole derivative
05/30/2012EP1701941B1 Compounds for treatment of cell proliferative diseases
05/30/2012EP1682116B1 Method for preparing submicron particles of paclitaxel or docetaxel
05/30/2012EP1670787B1 Cytokine inhibitors
05/30/2012EP1438302B1 New sulfonamide derivatives as d3-receptor ligands
05/30/2012EP1372619B1 Process for the production of a highly flexible transdermal therapeutic system having nicotine as active substance
05/30/2012EP1263465B1 Photodynamic cellular organism eradication using a photosensitive material and surfactant
05/30/2012EP1214298B1 Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
05/30/2012EP1178808B1 Non-aqueous pharmaceutical composition for dermal use to treat psoriasis comprising a vitamin d, a corticosteroid and a solvent component
05/30/2012CN202236441U Traditional Chinese medicine soup for treating heart tissue diseases and package thereof
1 ... 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 ... 7860